Opacorden (Amiodarone Hydrochloride)

Amiodarone Hydrochloride, the active ingredient in Opacorden, is a Class III antiarrhythmic presented as a strength/form for oral use. It treats life‑threatening ventricular and supraventricular arrhythmias in adult patients. GNH USA supplies Opacorden as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Opacorden as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Opacorden, a Class III antiarrhythmic, is used to manage serious cardiac rhythm disturbances.

- Ventricular tachycardia: helps restore normal rhythm and prevent recurrence. - Ventricular fibrillation: assists in stabilising the heart rhythm after defibrillation. - Atrial fibrillation/flutter: aids in maintaining sinus rhythm and controlling ventricular rate. - Supraventricular tachycardia: reduces episodes and supports rhythm control. - Prevention of postoperative arrhythmias: lowers the incidence of arrhythmias after cardiac surgery.

Amiodarone may present a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Photosensitivity - Blue‑g‑t‑g   - Skin rash   - Nausea - Fatigue - Tremor

Serious or Rare Side Effects: - Pulmonary fibrosis - Hepatic injury - Thyroid dysfunction (hypo‑ or hyper‑thyroidism) - Severe bradycardia - Vision loss (optic neuropathy).

When using Opad       ");

-  ");

");  

-  d ",